eScholarship
metadata only
CC BY-NC
Genetically Engineered Mesenchymal Stem Cells as a Proposed Therapeutic for Huntington’s Disease
There is much interest in the use of mesenchymal stem cells/marrow stromal cells (MSC) to treat neurodegenerative disorders, in particular those that are fatal and difficult to treat, such as Huntington’s disease. MSC present a promising tool for cell therapy and are currently being tested in FDA-ap
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis#874833
- An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196#896852
- Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.#867660
- Supplementary information for "CXCR2-dependent neuroprotection and synaptic remodeling by glia-like human mesenchymal stem cells in vascular dementia models"#1345411
- Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine#810089
Record · ID 1263379
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive